NCT01982331View on ClinicalTrials.gov

Reactogenicity, Safety and Immunogenicity of a Live Monovalent A/17/CALIFORNIA/66/395 (H2N2) Influenza Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

January 31, 2014

Study Completion Date

March 31, 2014

Conditions
Influenza
Interventions
BIOLOGICAL

LAIV H2N2

vaccine is delivered intranasally, .25 cc to each nostril at day 0 and day 28

OTHER

Placebo

placebo delivered intranasally. .25cc to each nostril at day 0 and day 28

Trial Locations (1)

Unknown

Research Institute of Influenza, Saint Petersburg

All Listed Sponsors
collaborator

Ministry of Health, Russian Federation

OTHER_GOV

collaborator

Institute of Experimental Medicine, Russia

OTHER

lead

PATH

OTHER

NCT01982331 - Reactogenicity, Safety and Immunogenicity of a Live Monovalent A/17/CALIFORNIA/66/395 (H2N2) Influenza Vaccine | Biotech Hunter | Biotech Hunter